borderline significantP = 0.03
Patients were followed up over a mean time of 21 months with 57% of deaths occurring in the EUS-FNA group and 76% in the non-EUS-FNA group, with EUS-FNA having a borderline significant association with improved overall survival (Hazard Ratio: 0.84, 95% confidence interval: 0.72–0.99, P = 0.03).[ 7 ] The authors of the study concluded that preoperative EUS-FNA did not adversely affect overall or cancer-specific survival and is, therefore, safe to be performed as part of the work-up of suspicious pancreatic lesions.